Literature DB >> 29087978

Prevalence and Factors Associated With Polypharmacy Use Among Adult Patients in Saudi Arabia.

Bander Balkhi, Nasser AlQahtani1, Monira Alwhaibi, Thamir M Alshammari, Tariq M Alhawassi, Mansour A Mahmoud2, Mansour Almetwazi, Sondus Ata3, Mada Basyoni3, Hisham Aljadhey1.   

Abstract

BACKGROUND: Polypharmacy is very common in clinical practice, especially among adult patients. The use of multiple medications may increase the risk of adverse drug events, medication cost, and medication errors. In addition, polypharmacy exacerbates treatment complexity, which consequently leads to poor patients' adherence to their medications. Despite being a well-recognized problem, few studies have investigated the prevalence and predictors of polypharmacy in Saudi Arabia.
OBJECTIVES: The aims of the study were to investigate the prevalence of polypharmacy among adult patients in a tertiary teaching hospital and to determine patients' characteristics that are associated with polypharmacy.
METHODS: This was a retrospective cross-sectional study using data extracted from the electronic health records database for a period of 6 months between January and June 2016 in outpatient setting. Descriptive statistics were used to analyze the study sample. A multivariate logistic regression model was used to examine the association between different variables and polypharmacy. Statistical analysis software (SAS 9.2) was used to analyze the study data.
RESULTS: A total of 17,237 observations (67.2% females) were included in the final analysis. Of these, nearly 54% (n = 9222) of reported observations were found using up to four prescription drugs and the other 46% (n = 8015) were using five or more prescription drugs. Interestingly, the prevalence of polypharmacy use was doubled among adults with hypertension as compared with those without hypertension (odds ratio [OR] = 2.68, 95% confidence interval [CI] = 2.51-2.87). In addition, polypharmacy use was two times more prevalent among adults with diabetes as compared with those without diabetes (OR = 2.31, 95% CI = 1.99-2.28) and five times more prevalent in patient with dementia (OR = 5.57, 95% CI = 1.26-24.7). Moreover, polypharmacy in adult patients was significantly influenced by sex (OR = 1.69, 95% CI = 1.59-1.80) and nationality (OR = 2.15, 95% CI = 2.00-2.31).
CONCLUSIONS: Polypharmacy is common among adult patients especially those who are older than 60 years. Polypharmacy may affect the overall process of drug therapy. It can be a risk factor to develop undesirable adverse drug events, especially in those with chronic health conditions. A special care should be taken to manage polypharmacy among adults in Saudi Arabia.
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 29087978     DOI: 10.1097/PTS.0000000000000439

Source DB:  PubMed          Journal:  J Patient Saf        ISSN: 1549-8417            Impact factor:   2.844


  7 in total

1.  Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.

Authors:  Monira Alwhaibi; Bander Balkhi; Tariq M Alhawassi; Hadeel Alkofide; Nouf Alduhaim; Rawan Alabdulali; Hadeel Drweesh; Usha Sambamoorthi
Journal:  BMJ Open       Date:  2018-05-24       Impact factor: 2.692

Review 2.  Current status, and future prospects of pharmaco-epidemiology and post-marketing surveillance in Saudi Arabia: A review of literature.

Authors:  Ashraf El-Metwally
Journal:  Saudi Pharm J       Date:  2018-03-06       Impact factor: 4.330

3.  Correlates of Psychotropic Polypharmacy in outpatient psychiatric clinics of two military tertiary hospitals in Saudi Arabia.

Authors:  Fares F Alharbi; Samar F Alharbi; Saleh Bin Salih; Khaled Al-Surimi
Journal:  J Family Community Med       Date:  2019 Sep-Dec

4.  Prevalence of Polypharmacy and Factors Associated with it Among Saudi Older Adults - Results from the Saudi National Survey for Elderly Health (SNSEH).

Authors:  Mohammad H Aljawadi; Abdullah T Khoja; Nouf M Alaboud; Maha E AlEnazi; Sulaiman A Al-Shammari; Tawfik A Khoja; Mansour S AlMuqbil; Abdulrahman M Alsheikh; Monira Alwhaibi
Journal:  Saudi Pharm J       Date:  2022-01-13       Impact factor: 4.562

Review 5.  National medicines policy development, Saudi Arabia.

Authors:  Khalid Almoteiry; Adel Alharf; Bandar Al Hammad; Ibrahim Aljuffali; Nahar Al-Azemi; Taghred Al-Ghaith; Shahad Alhomidi; Ahlam Alshehri; Andreas Seiter; Christopher Herbst; Elizabeth Pisani
Journal:  Bull World Health Organ       Date:  2022-06-22       Impact factor: 13.831

6.  Impact of Specialized Clinics on Medications Deprescribing in Older Adults: A Pilot Study in Ambulatory Care Clinics in a Teaching Hospital.

Authors:  Ghada Bawazeer; Saad Alsaad; Haya Almalag; Alhanouf Alqahtani; Noura Altulaihi; Abdulaziz Alodhayani; Abdulaziz AlHossan; Ibrahim Sales
Journal:  Saudi Pharm J       Date:  2022-04-30       Impact factor: 4.562

Review 7.  Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.

Authors:  Abdulaziz Ibrahim Alzarea; Yusra Habib Khan; Abdullah Salah Alanazi; Muhammad Hammad Butt; Ziyad Saeed Almalki; Abdullah K AlAhmari; Saud Alsahali; Tauqeer Hussain Mallhi
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.